Century Therapeutics, Inc.
General ticker "IPSC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $85.0M (TTM average)
Century Therapeutics, Inc. follows the US Stock Market performance with the rate: 41.3%.
Estimated limits based on current volatility of 2.7%: low 2.17$, high 2.29$
Factors to consider:
- Total employees count: 165 (-10.3%) as of 2023
- Top business risk factors: Limited operating history, Operational and conduct risks, Dependence on product candidates, Technological challenges, Gene editing technology risks
- Current price 29.9% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.60$, 1.78$]
- 2026-12-31 to 2027-12-31 estimated range: [0.60$, 1.71$]
Financial Metrics affecting the IPSC estimates:
- Positive: with PPE of -15.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -129.14 <= 0.07
- Positive: Investing cash flow per share per price, % of 133.65 > -0.65
- Positive: Shareholder equity ratio, % of 71.05 > 64.25
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term IPSC quotes
Long-term IPSC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.23MM | $6.59MM | $109.16MM |
| Operating Expenses | $148.78MM | $144.73MM | $124.20MM |
| Operating Income | $-146.55MM | $-138.14MM | $-15.04MM |
| Non-Operating Income | $11.75MM | $13.36MM | $5.39MM |
| Interest Expense | $0.54MM | $0.00MM | $0.00MM |
| R&D Expense | $97.71MM | $107.24MM | $95.67MM |
| Income(Loss) | $-134.79MM | $-124.78MM | $-9.65MM |
| Taxes | $1.88MM | $1.79MM | $-0.07MM |
| Profit(Loss)* | $-136.67MM | $-126.57MM | $-9.58MM |
| Stockholders Equity | $184.75MM | $161.36MM | $158.94MM |
| Assets | $360.69MM | $353.22MM | $223.70MM |
| Operating Cash Flow | $-88.35MM | $-110.14MM | $-103.88MM |
| Capital expenditure | $13.74MM | $0.15MM | $0.85MM |
| Investing Cash Flow | $61.13MM | $47.48MM | $107.50MM |
| Financing Cash Flow | $-9.72MM | $74.56MM | $0.17MM |
| Earnings Per Share** | $-2.30 | $-1.61 | $-0.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.